ICCC - ImmuCell Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0000
+0.1500 (+3.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.8500
Open4.0000
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range3.9800 - 4.0000
52 Week Range3.7000 - 8.1300
Volume18,064
Avg. Volume87,923
Market Cap28.852M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.1900
Earnings DateFeb 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
      Benzinga

      The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

      Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ: BNGO) (priced $18 million common stock and warrant offering) * Celcuity Inc (NASDAQ: CELC) * China SXT Pharmaceuticals Inc (NASDAQ: SXTC) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Mediwound Ltd (NASDAQ: MDWD) * Merus NV (NASDAQ: MRUS) * Myokardia Inc (NASDAQ: MYOK) * Neovasc Inc (NASDAQ: NVCN) * Opko Health Inc. (NASDAQ: OPK) * PDS Biotechnology Corp (NASDAQ: PDSB) * Phio Pharmaceuticals Corp (NASDAQ: PHIO) * Precipio Inc (NASDAQ: PRPO) * Seelos Therapeutics Inc (NASDAQ: SEEL) * Sellas Life Sciences Group Inc (NASDAQ: SLS) * Chanticleer Holdings Common Stock (NASDAQ: SONN) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ)'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.Janssen will contribute proprietary antigen-binding domains for up to four tumor-associated antigen targets, and pay Fate $50 million in cash and also subscribe to $50 million in the latter's common shares at $31 per share.Fate will be responsible for developing candidate until IND filing after which Janssen has the right to exercise options to license these.Fate is eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.Fate shares jumped 23.40% to $26 in after-hours trading.Sanofi, Regeneron Announces Positive Latestage Data For Dupixent-SoC Combo In Eczema In Kids Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced data from pivotal Phase 3 study of Dupixent combined with standard-of-care topical corticosteroidsin children aged 6-11 years with uncontrolled severe atopic dermatitis, which showed significantly improved disease signs, symptoms and health-related quality of life.The company said detailed results will be presented during a session at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference on Sunday.See Also: Attention Biotech Investors: Mark Your Calendar For These April PDUFA DatesNovartis, Incyte to Study Ruxolitinib For COVID-19 Related Cytokine Storm Novartis AG (NYSE: NVS) said it a plans to initiate a Phase 3 clinical trial in collaboration with Incyte Corporation (NASDAQ: INCY) to evaluate the use of ruxolitinib for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.Novartis said it is taking steps to manage the anticipated increase in COVID-19 related requests for Jakavi - trade name of ruxolitinib in territories outside of the U.S. - without interrupting access for patients taking the drug for its licensed indications.Novartis has licensed Jakavi from Incyte to commercialize in regions outside of the U.S., while Incyte markets it in the U.S. under the name Jakafi.Novartis shares gained 1.18% to $84.59 in after-hours trading, while Incyte stock rose 1% to 1.86% to $78.50 in after-hours trading.Immucell Pre-announces Q1 Net Product Sales Growth of 11.3% ImmuCell Corporation (NASDAQ: ICCC) announced preliminary first-quarter results, expecting product sales of $4.9 million, up 11.3% year-over-year.Savara Licenses Latestage Inhaled Antibiotic Asset From Grifols Savara Inc (NASDAQ: SVRA) said it has entered into an exclusive license and collaboration agreement with Grifols SA - ADR ADR Class B (NASDAQ: GRFS) for Apulmiq - inhaled liposomal ciprofloxacin. Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis.The agreement provides for Savara obtaining worldwide rights to develop and commercialize Apulmiq for an upfront payment. if regulatory approval is obtained, Grifols will be eligible for regulatory milestone payments as well as royalties and potential tiered sales milestones upon commercialization.Savara said it expects to work with regulatory agencies to plan a confirmatory Phase 3 study.The stock rallied 11.83% to $2.08 in after-hours trading.Emergent Biosolutions Gets $14.5M Grant For COVID-19 Therapy Development Emergent Biosolutions Inc (NYSE: EBS) said it has entered into a formal partnership with the U.S. government to expedite development of plasma-derived therapy for patients with COVID-19. The company said it has received $14.5 million from the BARDA for its COVID-HIG program - one of the hyperimmune development programs announced by the company in March.Announcements On COVID-related Impacts Updating on COVID-19 impact, Denali Therapeutics Inc (NASDAQ: DNLI), a neurodegenerative diseases-focused biopharma, said it does not expect delays to its clinical trials due to manufacturing or supply-chain issues. The company, however, said it has paused enrollment of new patients into some of its trials.The company also said it has sufficient cash to fund business operations through 2022.The stock slipped 2.41% to $17.02 in after-hours trading.Dynavax Technologies Corporation (NASDAQ: DVAX) announced withdrawal of its 2020 guidance, citing uncertainties about the duration and effect of the COVID-19 pandemic and the potential impact on hepatitis B vaccine - Heplisav-B - product sales.The company also said it has already exceeded the Heplisav-B minimum product revenue covenant in its term loan agreement of $30 million for the annual measurement period ending June 30.On The Radar Clinical Readout Prothena Corporation PLC (NASDAQ: PRTA) said its development partner Roche Holdings AG Basel ADR (OTC: RHHBY) will present baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease in an oral presentation at the Advances in Alzheimer's and Parkinson's Therapies AAT-AD/PD Focus Meeting being held virtually.IPO Zentalis Pharma, a biopharma focused on developing small molecule therapeutics targeting fundamental pathways of cancer, said it has priced its initial public offering of 9.18 million shares at $18 per share for raising gross proceeds of $165.2 million. The company expects the offering to close April 7. The shares are to be listed on the Nasdaq under the ticker symbol ZNTL.See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • GlobeNewswire

      ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the first quarter ended March 31, 2020. Total product sales increased by approximately 11.3%, or $500,000, to approximately $4.9 million during the quarter ended March 31, 2020 versus last year’s first quarter, which ended March 31, 2019. Total product sales increased by approximately 13.6%, or $1.7 million, to approximately $14.2 million during the trailing twelve-month period ended March 31, 2020 versus the trailing twelve-month period ended March 31, 2019.

    • GlobeNewswire

      ImmuCell Announces Refinancing of its Bank Debt

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a complete refinancing of its bank debt. The Company closed on an $8.6 million debt refinancing package with Gorham Savings Bank comprised of three components. The first is a ten-year $5.1 million mortgage note bearing interest at a fixed rate of 3.50% per annum with monthly principal and interest payments due based on a twenty-five-year amortization schedule.

    • Why ImmuCell Corporation's (NASDAQ:ICCC) CEO Pay Matters To You
      Simply Wall St.

      Why ImmuCell Corporation's (NASDAQ:ICCC) CEO Pay Matters To You

      In 2000 Michael Brigham was appointed CEO of ImmuCell Corporation (NASDAQ:ICCC). This report will, first, examine the...

    • Thomson Reuters StreetEvents

      Edited Transcript of ICCC earnings conference call or presentation 19-Feb-20 2:00pm GMT

      Full Year 2019 ImmuCell Corp Earnings Call

    • GlobeNewswire

      ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019

      PORTLAND, Maine, Feb. 19, 2020 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

    • GlobeNewswire

      ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2019

      PORTLAND, Maine, Feb. 18, 2020 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

    • GlobeNewswire

      ImmuCell to Announce Preliminary Financial Results for the Year Ended December 31, 2019

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2019 after the market closes on Tuesday, February 18, 2020. The Company has scheduled a conference call on Wednesday, February 19, 2020 at 9:00 AM ET  to review the 2019 results. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company.

    • Benzinga

      Why I Love Trading A Small Account, And Why You Should Too

      January is turning out to be a bit of a roller-coaster market for my main account. The last trade I took in the account on Wednesday in Neurotrope, Inc. (NASDAQ: NTRP) ended up netting me another $166 in the account.

    • Imagine Owning ImmuCell (NASDAQ:ICCC) And Wondering If The 32% Share Price Slide Is Justified
      Simply Wall St.

      Imagine Owning ImmuCell (NASDAQ:ICCC) And Wondering If The 32% Share Price Slide Is Justified

      Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

    • GlobeNewswire

      ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the year ended December 31, 2019. Total product sales increased by approximately $2,700,000, or 25%, to approximately $13,700,000 during the year ended December 31, 2019 versus the year ended December 31, 2018. Total product sales increased by approximately $695,000, or 24%, to approximately $3,600,000 during the fourth quarter ended December 31, 2019 versus the comparable period during 2018.

    • Thomson Reuters StreetEvents

      Edited Transcript of ICCC earnings conference call or presentation 11-Nov-19 9:30pm GMT

      Q3 2019 ImmuCell Corp Earnings Call

    • Hedge Funds Have Never Been More Bullish On ImmuCell Corporation (ICCC)
      Insider Monkey

      Hedge Funds Have Never Been More Bullish On ImmuCell Corporation (ICCC)

      Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]

    • Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?
      Simply Wall St.

      Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?

      Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

    • Does ImmuCell Corporation (NASDAQ:ICCC) Have A Volatile Share Price?
      Simply Wall St.

      Does ImmuCell Corporation (NASDAQ:ICCC) Have A Volatile Share Price?

      If you own shares in ImmuCell Corporation (NASDAQ:ICCC) then it's worth thinking about how it contributes to the...

    • GlobeNewswire

      ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

      PORTLAND, Maine, Nov. 11, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

    • GlobeNewswire

      ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle - will report unaudited financial results for the quarter ended September 30, 2019 after the market closes on Monday, November 11, 2019. The Company has scheduled a conference call that evening, Monday, November 11, 2019, at 4:30 PM ET to review the results. Interested parties can access the conference call scheduled by the Company to review these results by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 4:30 PM ET on Monday, November 11, 2019.

    • GlobeNewswire

      ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a lease covering approximately 14,300 square feet of office and warehouse space effective approximately November 1, 2019.

    • GlobeNewswire

      ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a new agreement with Norbrook Laboratories, Limited of Newry, Northern Ireland covering the formulation and aseptic filling of its Nisin Drug Substance into syringes for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in dairy cows. The new agreement (which replaces an expiring agreement) expires as of December 31, 2021 and allows for product ordered before the expiration date to be delivered into the early part of 2022.

    • Thomson Reuters StreetEvents

      Edited Transcript of ICCC earnings conference call or presentation 13-Aug-19 1:00pm GMT

      Q2 2019 ImmuCell Corp Earnings Call

    • GlobeNewswire

      ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

      ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has received a response from the U.S. Food and Drug Administration (FDA) to its first phased Nisin Drug Substance submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in lactating dairy cows.

    • GlobeNewswire

      ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

      PORTLAND, Maine, Aug. 12, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

    • Benzinga

      The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

      Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...

    • GlobeNewswire

      ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019

      PORTLAND, Maine, Aug. 06, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets.

    • Thomson Reuters StreetEvents

      Edited Transcript of ICCC earnings conference call or presentation 14-May-19 1:00pm GMT

      Q1 2019 ImmuCell Corp Earnings Call